Jupiter Neurosciences, Inc. (JUNS)
JUNS moved a median of -2.06% 30 minutes after news, and -1.46% by the close. How JUNS actually reacts to news — the realized, point-in-time move the market made, measured across 98 labeled events over the last three years with zero look-ahead.
JUNS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.20% | 39% | 94 |
| 30-min | -2.06% | 42% | 98 |
| 60-min | -0.56% | 36% | 98 |
| to close | -1.46% | 39% | 96 |
| Middle 50% of JUNS reactions | -3.13% to +1.23% |
|---|---|
| Median reaction (30-min) | -2.06% |
| Measured reactions | 98 |
Half of all Jupiter Neurosciences, Inc. news events land between -3.13% and +1.23% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when JUNS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to JUNS's baseline. Nothing else.
Recent JUNS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form S-8 JUPITER NEUROSCIENCES, | SEC filing · Form S-8 | SEC EDGAR | +1.33% | +12.00% | |
| Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value | Press release | GlobeNewswire | -3.61% | +12.60% | |
| Form S-3 JUPITER NEUROSCIENCES, | SEC filing · Form S-3 | SEC EDGAR | +0.00% | -5.32% | |
| Form D JUPITER NEUROSCIENCES, | SEC filing · Form D | SEC EDGAR | +0.00% | -3.75% | |
| Form 8-K JUPITER NEUROSCIENCES, For: Aug 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -5.78% | |
| Form 8-K JUPITER NEUROSCIENCES, For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | +1.67% | +18.00% | |
| Form 8-K JUPITER NEUROSCIENCES, For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | -1.46% | -1.01% | |
| Form 8-K JUPITER NEUROSCIENCES, For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | +4.52% | +0.18% | |
| Form 8-K JUPITER NEUROSCIENCES, For: Aug 24 | SEC filing · Form 8-K | SEC EDGAR | -1.68% | -7.35% | |
| Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering | Press release | GlobeNewswire | -1.07% | -17.34% | |
| Form 10-Q JUPITER NEUROSCIENCES, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.16% | +1.57% | |
| Form 8-K JUPITER NEUROSCIENCES, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -2.54% | -4.82% | |
| Jupiter Neurosciences, Inc. Announces Reverse Stock Split | Press release | GlobeNewswire | -5.28% | -12.50% | |
| Form 8-K JUPITER NEUROSCIENCES, For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -7.91% | |
| Form 8-K JUPITER NEUROSCIENCES, For: Jul 22 | SEC filing · Form 8-K | SEC EDGAR | -4.41% | -10.63% | |
| Form 8-K JUPITER NEUROSCIENCES, For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | +6.22% | +27.73% | |
| Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million | Press release | GlobeNewswire | +0.70% | -24.95% | |
| PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 | Press release | GlobeNewswire | +0.70% | -24.95% | |
| Form EFFECT JUPITER NEUROSCIENCES, | SEC filing · Form EFFECT | SEC EDGAR | -0.91% | -7.22% | |
| Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson | Press release | GlobeNewswire | -0.72% | -2.66% | |
| Form 8-K JUPITER NEUROSCIENCES, For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | -4.78% | -3.15% | |
| Form S-1 JUPITER NEUROSCIENCES, | SEC filing · Form S-1 | SEC EDGAR | +5.69% | +1.30% | |
| Form 8-K JUPITER NEUROSCIENCES, For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | -1.83% | -4.17% | |
| Form ARS JUPITER NEUROSCIENCES, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.83% | -4.17% | |
| Form DEF 14A JUPITER NEUROSCIENCES, For: Jun 22 | SEC filing · Form DEF | SEC EDGAR | -1.83% | -4.17% | |
| Form PRE 14A JUPITER NEUROSCIENCES, For: Jun 09 | SEC filing · Form PRE | SEC EDGAR | +1.12% | +0.45% | |
| Form 8-K JUPITER NEUROSCIENCES, For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | +0.04% | -3.75% | |
| Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease | Press release | GlobeNewswire | +0.29% | +7.63% | |
| Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering | Press release | GlobeNewswire | +0.00% | -6.71% | |
| Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering | Press release | GlobeNewswire | -14.09% | -36.92% | |
| Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech | Press release | GlobeNewswire | -6.62% | -60.12% | |
| PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million | Press release | GlobeNewswire | -6.62% | -60.12% | |
| Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board | Press release | GlobeNewswire | — | -2.17% | |
| Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream | Press release | GlobeNewswire | +3.05% | -0.08% | |
| Jupiter Neurosciences to Present at Emerging Growth Conference on April 2 | Press release | GlobeNewswire | +1.43% | +12.33% | |
| Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026 | Press release | GlobeNewswire | +3.74% | +1.36% | |
| Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago | Press release | GlobeNewswire | -4.59% | +2.50% | |
| Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution | Press release | GlobeNewswire | +10.24% | +4.00% | |
| Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users | Press release | GlobeNewswire | -4.11% | -13.59% | |
| Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference | Press release | ACCESS Newswire | -0.93% | +0.60% | |
| Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6 | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum | Press release | GlobeNewswire | +0.00% | +2.54% | |
| Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease | Press release | GlobeNewswire | -2.36% | +7.09% | |
| Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing | Press release | GlobeNewswire | +0.00% | +6.92% | |
| Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador | Press release | GlobeNewswire | +0.67% | +7.38% | |
| Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements | Press release | GlobeNewswire | +2.42% | +2.78% | |
| Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador | Press release | GlobeNewswire | -2.26% | — | |
| Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience | Press release | GlobeNewswire | -2.40% | -8.00% | |
| Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science | Press release | GlobeNewswire | +7.09% | +3.59% | |
| Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | GlobeNewswire | +8.90% | +19.89% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the JUNS section they belong to.
Where else JUNS is measured.
JUNS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Jupiter Neurosciences, Inc.'s median reaction calculated?
Every labeled JUNS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 98 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of JUNS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does JUNS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.